Preventive PCI versus optimal medical therapy only for vulnerable plaques
Marc Bonaca, MD
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
Brian Bergmark, MD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Michael Koren, MD
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Michael Gibson, MD
Loading...
We’re glad to see you’re enjoying PACE-CME…but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.